Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced three presentations at upcoming investor and industry conferences. Jak Knowles, M.D., Co-founder, President and Chief Executive Officer of Affini-T Therapeutics, will present at each discussing the company’s T cell receptor (TCR) discovery platform, lead programs targeting KRAS G12V and G12D and clinical-stage program against Merkel cell carcinoma. A copy of the company’s corporate presentation and webcast link will be available under Corporate Presentations in the News section of its website following the meetings.

“This is an exciting time for KRAS and T cell receptor therapies given the significant advances in research, including the recent report in The New England Journal of Medicine that details the promising clinical response of a patient with metastatic pancreatic cancer by targeting the KRAS G12D driver mutation,” said Dr. Knowles. “At these upcoming meetings, we look forward to connecting with investor and industry contacts to discuss how we can work together to unlock the full potential of this field and bring potentially curative treatments to patients facing some of the most difficult-to-treat solid tumor cancers.”

Presentation details are as follows:

Conference: Jefferies Global Healthcare Conference (access to webcast)

Date: June 8, 2022

Time: 4:30 pm EDT

Location: New York, New York

Conference: BIO International Convention

Date: June 13, 2022

Time: 03:30 pm PDT

Location: San Diego, California

Conference: JMP Securities Life Sciences Conference

Date: June 15, 2022

Time: 12:00 pm EDT

Location: New York, New York

About Affini-T Therapeutics

Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006414/en/